Beacon Rise Terminates Cowes Chiropractic Acquisition Amid Due Diligence, Shares Remain Suspended

Beacon Rise drops Cowes Chiropractic deal after due diligence

Beacon Rise Holdings Plc has walked away from its proposed acquisition of Lyfe Health Isle of Wight Limited, which trades as Cowes Chiropractic. The deal, first outlined on 4 November 2025, was expected to be around £0.5 million for the entire issued and to be issued share capital. After reviewing commercial and financial due diligence, the board decided it was not in shareholders’ best interests to proceed and has terminated discussions with immediate effect.

There is no colour on what the due diligence turned up – it’s simply not disclosed. But the signal is clear: the board is prioritising deal quality over deal pace. For a small acquisition like this, discipline matters just as much as ambition.

What remains in Beacon Rise’s pipeline

The company says it is still progressing due diligence on three previously announced deals:

• The Proposed Ergotec Acquisition
• The Proposed Chiropractor Acquisition
• The Proposed Training-provider Acquisition

Crucially, these are all separate and not inter-conditional. In plain English: if one falls over, the others can still go ahead. That reduces the risk of a domino effect if a single transaction proves unworkable.

Why the shares remain suspended under UK Listing Rules

Beacon Rise’s ordinary shares of £1.00 each (ISIN: GB00BMC0V753) remain suspended from the equity shares (shell companies) segment of the FCA’s Official List and from trading on the Main Market of the London Stock Exchange. The company states this is in line with UK Listing Rules 21.1.4 and 21.3, because the proposed deals are classified as an “initial transaction” under UKLR 13.4.

Quick jargon check:

• Initial transaction – for a listed shell company, the first substantive acquisition that will define its business going forward.
• Suspension – temporary halt to trading and listing while material change or uncertainty is addressed.

Beacon Rise will issue a further announcement if final terms for any of the proposed acquisitions are agreed, as required by UKLR 13.4.22R and 13.4.23R.

Key risks and contingencies spelled out

The RNS is clear that there is no certainty the proposed acquisitions will complete, nor clarity on timing or final terms. If none of the proposed acquisitions complete, the company expects – subject to FCA approval – that suspension would be lifted and trading would recommence. That at least offers a backstop route to restoring liquidity if the pipeline fails to convert.

However, Beacon Rise also signals a potential strategic pivot point. It will seek to sign final binding agreements on the proposed acquisitions simultaneously prior to “Cancellation and Admission”. If it secures at least one binding agreement, it intends to proceed with Cancellation and Admission regardless. In context, that typically means cancelling the current listing status and seeking admission of the company’s shares in connection with its new operating business. The precise mechanics are not spelled out in the RNS, but investors should be prepared for corporate housekeeping alongside any deal completion.

My take: pragmatic decision, but suspension drags

On balance, dropping Cowes Chiropractic looks like sensible risk management. Paying approximately £0.5 million for a clinic only makes sense if the diligence stacks up on quality of earnings, sustainability of patient flow, and clean financials. The board’s conclusion that it was not in shareholders’ best interests to proceed suggests red flags or a mismatch on valuation or terms.

The frustration for holders is the ongoing suspension. Illiquidity can be painful, especially when timelines are not disclosed. The mitigants here are that (a) there are three other deals still in diligence, (b) they are not inter-conditional, so any one could carry the strategy forward, and (c) if nothing completes, the company expects to resume trading, subject to the FCA.

Overall, I’d score this update as mixed. Positive for governance and capital discipline. Negative for near-term visibility and the continued trading halt. Execution now matters more than ever – one signed, binding agreement would be a material step towards clarity.

What to watch next from Beacon Rise

• Any announcement of agreed final terms on the Ergotec, Chiropractor, or Training-provider deals, per UKLR 13.4.22R and 13.4.23R.
• Clarification on “Cancellation and Admission” timing and sequencing once a binding deal is signed.
• Updates if any additional proposed acquisitions are dropped following diligence.
• Confirmation of suspension being lifted if the acquisition pipeline does not complete.

Quick explainer: terms used in this RNS

• Heads of terms – a non-binding outline of a deal’s key points. It sets intent but is not a final contract.
• Due diligence – the buyer’s deep dive into the target’s finances, contracts, operations, and risks before signing binding terms.
• Inter-conditional – when multiple deals are tied together. Here they are not inter-conditional, so each can proceed independently.
• Cancellation and Admission – cancel the current listing and apply for admission to listing and trading in connection with the company’s go-forward structure. The RNS does not disclose the precise timetable.

Key figures and regulatory details at a glance

Target	Lyfe Health Isle of Wight Limited (trading as Cowes Chiropractic)
Proposed consideration	Approximately £0.5 million
Heads of terms announced	4 November 2025
Termination announced	2 February 2026
Listing status	Shares remain suspended from the Official List (equity shares – shell companies) and Main Market trading
Share details	Ordinary shares of £1.00 each, ISIN: GB00BMC0V753
Other proposed deals	Ergotec, a Chiropractor business, and a Training-provider
Completion certainty	No certainty on completion, timing, or final terms

Bottom line for retail investors

Discipline over dealmaking is usually the right call, but it extends the waiting game. Beacon Rise has three shots on goal, any one of which could unlock the next phase of its strategy. Until then, shares remain suspended, timelines are not disclosed, and risk sits with execution. Keep an eye out for binding terms – that is the next meaningful catalyst flagged by the company.

Regulatory note

The company flagged this as inside information under the UK Market Abuse Regulation. Sponsor and financial adviser is Allenby Capital Limited. Company Secretary is LDC Nominee Secretary Limited.